Strides Pharma Science Limited
NSE: STARMarket Closed • NSE
Day range
52 week range
Strides Pharma Science Limited closed at INR1085.30 (-0.91%) on volume 0.79x its 20-day average, trading 13.93% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved +27.9% QoQ
2026-07-31
DIVIDEND Announced
Dividend - Rs 5 Per Share
2025-07-22
DIVIDEND Announced
Dividend - Rs 4 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 18.3%
Attractive Valuation: P/E of 16.3x trades below sector historical averages
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 31 Jul 2026 | Dividend | ₹5.00 / share | — | 31 Jul 2026 |
| 22 Jul 2025 | Dividend | ₹4.00 / share | — | 22 Jul 2025 |
| 06 Dec 2024 | Demerger | Demerger | — | 06 Dec 2024 |
| 09 Sept 2024 | Dividend | ₹2.50 / share | — | 09 Sept 2024 |
| 04 Aug 2023 | Dividend | ₹1.50 / share | — | 04 Aug 2023 |
| 06 Aug 2021 | Dividend | ₹2.50 / share | — | 05 Aug 2021 |
| 27 Jul 2020 | Dividend | ₹2.00 / share | — | 24 Jul 2020 |
| 23 Aug 2019 | Dividend | ₹12.00 / share | — | 22 Aug 2019 |
| — | Dividend | ₹3.00 / share | — | 19 Jul 2019 |
| — | Dividend | ₹2.00 / share | — | 12 Sept 2018 |
| 09 Apr 2018 | Scheme Of Arrangement | Scheme Of Arrangement | — | 06 Apr 2018 |
| — | Dividend | ₹4.50 / share | — | 07 Sept 2017 |
| — | Dividend | ₹4.00 / share | — | 21 Jul 2016 |
| — | Dividend | ₹3.00 / share | — | 22 Jul 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.92 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.48L | 84.75 | 0.32% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.77L | 74.39 | 0.82% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.17L | 183.15 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.15L | 55.26 | 0.26% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.11L | 24.91 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.10L | 100.67 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.05L | 31.20 | 0.99% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2] The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]
IndiaHealthcare
Is Strides Pharma Science Limited Shariah compliant?
Strides Pharma Science Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (17.57%) complies with AAOIFI threshold (≤ 33%).
What is Strides Pharma Science Limited's current valuation relative to peers?
Strides Pharma Science Limited trades at a P/E of 16.3x compared to the sector median of 37.6x, and a Price-to-Book of 3.2x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.56x. Interest coverage is 4x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 5.4% while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-09. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.